ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

导出 OA

翻译打印收藏纠错

作者： Angel L,Guerrero-Zotano ^[1] ; Thomas P,Stricker ^[2] ; Luigi,Formisano ^[1] ; Katherine E,Hutchinson ^[1] ; Daniel G,Stover ^[3] ; Kyung-Min,Lee ^[1] ; Luis J,Schwarz ^[1] ; Jennifer M,Giltnane ^[2] ; Monica V,Estrada ^[4] ; Valerie M,Jansen ^[1] ; Alberto,Servetto ^[1] ; Joaquín,Gavilá ^[5] ; J Alejandro,Perez-Fidalgo ^[6] ; Ana,Lluch ^[6] ; Antonio,Llombart-Cussac ^[7] ; Mohamed Amine,Bayar ^[8] ; Stefan,Michiels ^[9] ; Fabrice,André ^[8] ; Mónica,Arnedos ^[9] ; Vicente,Guillem ^[10] ; Amparo,Ruiz-Simon ^[10] ; Carlos L,Arteaga ^[5]

作者单位： Departments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. ^[1] Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee. ^[2] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[3] Breast Cancer Program, Vanderbilt University Medical Center, Nashville, Tennessee. ^[4] Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain. ^[5] Department of Oncology and Hematology, Hospital ClinicoUniversitario, INCLIVA Biomedical Research Institute, University of Valencia, CIBERONC, Valencia, Spain. ^[6] Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain. ^[7] Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France. ^[8] CESP, Faculté de Médecine, Université Paris Sud, Faculté de Médecine UVSQ, INSERM, Université Paris Saclay, Villejuif, France. ^[9] Department of Medical Oncology, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France. ^[10] Departments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. carlos.arteaga@utsouthwestern.edu. ^[11] Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. ^[12]